Elotuzumab in multiple myeloma

Expert Opin Biol Ther. 2023 Jan;23(1):7-10. doi: 10.1080/14712598.2022.2145882. Epub 2022 Nov 14.

Affiliations

¹ Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.
² Department of Experimental and Clinical Medicine, University "Magna Graecia" of Catanzaro, Catanzaro, Italy.
³ Direzione Generale, Ospedaliera Annunziata, Cosenza, Italy.
⁴ Scientific Directorate IRCCS of Reggio Emilia, I-42123 Reggio Emilia, Emilia-Romagna, Italy.
⁵ Biotechnology Research Unit, AO of Cosenza, Cosenza, Italy.

PMID: 36373842
DOI: 10.1080/14712598.2022.2145882

No abstract available

Keywords: Elotuzumab; multiple myeloma; therapy.

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Dexamethasone / therapeutic use
Humans
Lenalidomide / therapeutic use
Multiple Myeloma* / drug therapy

Substances

elotuzumab
Antibodies, Monoclonal, Humanized
Lenalidomide
Dexamethasone